WHO ICTRP trial
A Phase 2a, Double Blind, Randomized, Placebo-controlled, 28 day, Two-arm…
EUCTR2009-014263-40-GB · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2009-014263-40-GB |
|---|---|
| Public title | A Phase 2a, Double Blind, Randomized, Placebo-controlled, 28 day, Two-arm, Parallel Group Study of A0001 in Patients with the A3243G Mitochondrial DNA Point Mutation and Evidence of Impaired Mitochondrial Function - MEL01. A0001 in Patients with A3243G Mitochondrial DNA Mutation |
| Scientific title | A Phase 2a, Double Blind, Randomized, Placebo-controlled, 28 day, Two-arm, Parallel Group Study of A0001 in Patients with the A3243G Mitochondrial DNA Point Mutation and Evidence of Impaired Mitochondrial Function - MEL01. A0001 in Patients with A3243G Mitochondrial DNA Mutation |
| Primary sponsor | Penwest Pharmaceuticals Co. |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Countries | United Kingdom |
| Conditions | A3243G mitochondrial DNA point mutation and evidence of impaired mitochondrial function |
| Interventions | Product Name: alpha-tocopherolquinone Product Code: A0001 Pharmaceutical Form: Capsule, hard Current Sponsor code: A0001 Other descriptive name: alpha-tocopherolquinone Concentration unit: mg milligram(s) Concentration type: equal… |
| Registration date | Nov 9, 2009 |
| Target size | 30 |
| Secondary IDs | MEL01 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: